Mechanisms of Disease: the role of heat-shock protein 90 in genitourinary malignancy
Open Access
- 1 November 2006
- journal article
- review article
- Published by Springer Science and Business Media LLC in Nature Reviews Endocrinology
- Vol. 3 (11), 590-601
- https://doi.org/10.1038/ncpuro0604
Abstract
Insight into the molecular biology of cancer has allowed the development of novel therapeutic strategies that target specific oncogenic pathways. Molecular therapeutic strategies are now part of the armamentarium available against urologic malignancy. Among the many targets of interest in urologic cancer, heat-shock protein 90 (HSP90) shows great promise. This molecule has a major role in prostate as well as in renal malignancy. In contrast to other targets, where cancer might escape inhibition via alternative pathways, HSP90 operates at multiple checkpoints in a cancer cell. Its inhibition could, therefore, prove more difficult for neoplastic cells to overcome. Inhibitors of HSP90, such as geldanamycin and its derivatives (17-allylamino-17-demethoxygeldanamycin and 17-dimethylaminoethylamino-17-demethoxygeldanamycin, known as 17AAG and 17DMAG, respectively) are available and have shown activity both in vivo and in vitro. 17AAG is currently being tested for efficacy in humans after having completed phase I trials, while 17DMAG is still in phase I evaluation. Phase II trials of HSP90 inhibitors in urologic malignancy are being conducted in kidney and advanced prostate cancer. Beyond monotherapy, HSP90 inhibitors might also prove to be beneficial in combination therapy with other chemotherapeutic agents in advanced disease. Studies being conducted in prostate cancer will hopefully help to define this potential application better.Keywords
This publication has 68 references indexed in Scilit:
- 4-Amino derivatives of the Hsp90 inhibitor CCT018159Bioorganic & Medicinal Chemistry Letters, 2006
- A yeast-based assay reveals a functional defect of the Q488H polymorphism in human Hsp90αBiochemical and Biophysical Research Communications, 2005
- Phase I Pharmacokinetic and Pharmacodynamic Study of 17-Allylamino, 17-Demethoxygeldanamycin in Patients With Advanced MalignanciesJournal of Clinical Oncology, 2005
- Molecular variation of human HSP90α and HSP90β genes in CaucasiansHuman Mutation, 2003
- The Assembly and Intermolecular Properties of the hsp70-Hop-hsp90 Molecular Chaperone ComplexPublished by Elsevier BV ,2002
- Hsp90 Regulates a von Hippel Lindau-independent Hypoxia-inducible Factor-1α-degradative PathwayPublished by Elsevier BV ,2002
- Hsp90 Regulates Androgen Receptor Hormone Binding Affinity in VivoPublished by Elsevier BV ,1996
- Polyubiquitination and Proteasomal Degradation of the p185c-B-2 Receptor Protein-tyrosine Kinase Induced by GeldanamycinJournal of Biological Chemistry, 1996
- Mutations of the VHL tumour suppressor gene in renal carcinomaNature Genetics, 1994
- The androgen receptor in LNCaP cells contains a mutation in the ligand binding domain which affects steroid binding characteristics and response to antiandrogensThe Journal of Steroid Biochemistry and Molecular Biology, 1992